pharma · Cystic Fibrosis · Multiple Sclerosis · RARE
Ultragenyx UK
Ultragenyx UK Limited
Ultragenyx UK clinical programs — 201 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Newcastle upon tyne, NE128RL, GB, NOVATO, CA
- Founded
- 2024
- Employees
- 2
- Programs
- 201
- Drugs
- 168
- Patents
- 23
Ultragenyx UK projects
201 ClinicalTrials.gov programs sponsored by Ultragenyx UK.
Ultragenyx UK has 201 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
fructose
Ultragenyx UK Limited
Sickle Cell Anemia
1 trial -
growth hormone
Ultragenyx UK Limited
Werner's Syndrome
1 trial -
megestrol
Ultragenyx UK Limited
Acquired Immunodeficiency Syndrome
1 trial -
midodrine
Ultragenyx UK Limited
Syncope
1 trial -
pancrelipase with bicarbonate
Ultragenyx UK Limited
Cystic Fibrosis
1 trial -
phosphatidylcholine
Ultragenyx UK Limited
Methionine Adenosyltransferase Deficiency
1 trial -
succimer
Ultragenyx UK Limited
Lead Poisoning
1 trial -
thioctic acid
Ultragenyx UK Limited
Mitochondrial Myopathy
1 trial -
thyrotropin-releasing hormone
Ultragenyx UK Limited
Respiratory Distress Syndrome
1 trial
Frequently asked questions
How many clinical projects does Ultragenyx UK have?
201 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.